

IN RE APPLICATION OF: Crooke et al.  
SERIAL NO: 09/918,026  
Response to Office Action Dated: Nov. 18, 2004

AMENDMENT TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

1. (Currently Amended) An antisense oligonucleotide 8 to 50 nucleobases in length targeted to ~~[[a]]~~the coding region of a nucleic acid molecule encoding human acyl CoA cholesterol acyltransferase-2 (SEQ ID NO: 3), wherein said ~~compound~~antisense oligonucleotide specifically hybridizes with said region and inhibits the expression of a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2 by at least ~~[[40%]]~~60%.

2. (Canceled)

3. (Canceled)

4. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.

5. (Previously Presented) The antisense oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.

7. (Previously Presented) The antisense oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-O-

IN RE APPLICATION OF: Crooke et al  
SERIAL NO: 09/918,026  
Response to Office Action Dated: Nov. 18, 2004

methoxyethyl sugar moiety.

8. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.

9. (Previously Presented) The antisense oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (Previously Presented) The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.

11. (Canceled).

12. (Previously Presented) A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

Claims 14-20 (Canceled)